Objective This study aims to synthesize cost and health outcomes for current treatment pathways for esophageal adenocarcinoma and high-grade dysplasia (HGD) and to model comparative net clinical and economic benefits of alternative management scenarios. Methods A decision-analytic model of real-world practices for esophageal adenocarcinoma treatment by tumor stage was constructed and validated. The model synthesized treatment probabilities, survival, quality of life, and resource use extracted from epidemiological datasets, published literature, and expert opinion. Comparative analyses between current practice and five hypothetical scenarios for modified treatment were undertaken. Results Over 5 years, outcomes across T stage ranged from 4.06 quality-adjusted life-years and costs of $3,179 for HGD to 1.62 quality-adjusted life-years and costs of $50,226 for stage T4. Greater use of endoscopic mucosal resection for stage T1 and measures to reduce esophagectomy mortality to 0-3 % produced modest gains, whereas a 20 % reduction in the proportion of patients presenting at stage T3 produced large incremental net benefits of $4,971 (95 % interval, $1,560-8,368). Conclusion These findings support measures that promote earlier diagnosis, such as developing risk assessment processes or endoscopic surveillance of Barrett's esophagus. Incremental net monetary benefits for other strategies are relatively small in comparison to predicted gains from early detection strategies.
Introduction
Esophagectomy is currently the standard surgical treatment for esophageal adenocarcinoma. However, only 25-35 % of patients presenting with this disease actually undergo surgery, either due to metastatic disease or comorbidities. New endoscopic techniques such as endoscopic mucosal resection (EMR) offer a new approach for early stage disease. EMR can be used to assess the depth of tumor invasion, and in some cases, it is definitive treatment. Further, the combination of EMR and radiofrequency ablation (RFA) is emerging as an option for more diffuse intramucosal disease. [1] [2] [3] [4] Few studies have assessed the cost-effectiveness of treatments for esophageal cancer and high-grade dysplasia (HGD). Pohl et al. 24 assessed the cost-effectiveness of combination EMR/RFA in patients with stage T1a esophageal adenocarcinoma and suggested that RFA was cost-effective over a 5-year time frame 1 . Similarly, a UK study by Boger et al. 23 compared first-line RFA (with esophagectomy for subsequent recurrence/ progression) versus esophagectomy in patients with HGD, and although modeling was limited to 2 years follow-up, they concluded that RFA was a cost-effective option.
Studies have produced mixed results for benefits for early cancer detection in Barrett's esophagus surveillance programs. 5 To date, there is a lack of evidence on crucial data estimates (e.g., quality of life, proportion of patients progressing from low-grade dysplasia to HGD), and analyses have not adequately scrutinized the clinical uncertainty of alternative management options. 5 Compared with other gastrointestinal cancers, there is limited evidence about the cost and health impact of new or modified strategies for controlling esophageal adenocarcinoma. These include substituting esophagectomy with endoscopic therapies (EMR/RFA) or chemoradiotherapy, concentrating surgical work to high-volume centers, and early testing of tumor response during neoadjuvant chemotherapy by positron emission tomography (PET) scan with subsequent targeted care.
To address questions of cost-effectiveness, it is necessary to understand the baseline health resource use and outcomes for treating esophageal adenocarcinoma or HGD in a way that reflects real-world practice. 6 An overview of the major practice patterns, natural history, and management of esophageal cancer and the associated health care resources used in a large Australian patient cohort (n 01,100) has been reported recently. 6 To better evaluate the current range of treatment options, we examined treatment pathways and outcomes for esophageal adenocarcinoma, as well as Barrett's esophagus with HGD. Patient survival, health-related quality of life and associated events, resource use from associated treatments, and cost were estimated for current management pathways, and a decision-analytic health economic model was developed. Alternative hypothetical management scenarios were then compared to current pathways to estimate potential benefits for alternative scenarios and management strategies.
Materials and Methods

Model Structure
A decision-analytic model was constructed in TreeAge Pro 2011 software (TreeAge Software Inc., Williamstown, MA, USA) (Fig. 1a, b) . This model explicitly identified the sequence and linkage of the major treatment pathways for different stages (T1-T4) of esophageal adenocarcinoma and also for HGD in Barrett's esophagus and tracked cohorts of patients with these diagnoses. The time horizon extended to 5 years after diagnosis, as this is the maximum duration for which reliable outcome data were available. To ensure that the model reproduced real-world practice, the medical pathways were identified and independently confirmed by five specialist upper gastrointestinal surgeons who were all actively engaged in esophageal cancer management. Several iterations of the model were constructed before the model was finalized, with consensus reached when it was necessary to balance treatment complexity with data availability.
The model pathways were first divided into T stages (i.e., American Joint Committee for Cancer tumor stages T1 to T4) at diagnosis, and separate pathways were also constructed for patients with distant metastases and patients presenting with HGD. The use of T stage rather than TNM stage was necessary because T stage can be determined for all patients undergoing endoscopic and surgical therapy, but N stage can only be identified accurately among surgical patients and can be distorted by chemoradiation treatment. Thus, to mandate the use of N scores in these analyses would introduce a staging bias. Pathways for stages T2 to T4 were structurally identical, with patients receiving either nonsurgical treatment or surgical treatment, with or without neoadjuvant therapies (Fig. 1b) , although the probabilities of different outcomes differed according to clinical stage. Those undergoing surgical treatment (with or without neoadjuvant therapy) followed paths where they either died perioperatively, died after tumor recurrence with distant metastases, died after a period of time from unrelated causes, or remained alive with no tumor recurrence at 5 years. Pathways for T1 stage and HGD were more complex (Fig. 1a) and also included endoscopic ablation of Barrett's esophagus and EMR options, either alone or prior to tumor recurrence and subsequent esophagectomy. Specifically, patients with T1b tumors predominantly received esophagectomy, while patients with T1a received definitive EMR. The model allocated patients to stages and associated treatment pathways according to mutually exclusive probabilities (Table 1) . Health outcomes and costs were assigned to the terminal node of each pathway, and values were calculated for each course of action along the decision tree. 7 
Data Sources
The main types of data in the model were treatment probabilities, survival (years), utilities (i.e., preference-based healthrelated quality of life), and medical costs. Data used to populate the model were based where feasible on the Australian Cancer Study Clinical Follow-Up Study (ACS), a "patterns of care" study which included 795 patients with esophageal adenocarcinoma or gastroesophageal junction adenocarcinomas. These patients were recruited between 2002 and 2008, had a mean age of 62 years, 61 % were men, predominantly Caucasian, and 25 % were current smokers. 8 ACS data were supplemented with data from prospectively collected datasets stored in databases and maintained by the major esophageal cancer units in Adelaide and Brisbane, Australia. These datasets contained outcome data from more than 2,000 individuals with esophageal cancer and more than 1,000 patients who had undergone an esophagectomy. Other treatment probabilities were determined from review of published literature and Australian all-cause mortality data (Table 1) . Odds ratios were applied to baseline risk to consistently model treatment effects on absolute incremental survival. 9 As the ACS included only patients with invasive esophageal adenocarcinoma, we reviewed the literature (for the search terms, see Appendix 1) to obtain treatment estimates for patients presenting with HGD and then checked these data for consistency against the prospective database maintained in Adelaide, South Australia. Remaining gaps in evidence to populate the decision tree were derived from consensus views of the five surgeons (expert opinion) (see Appendix 2) . Furthermore, at least two of the surgeons involved also have significant experience in endoscopic management of HGD and T1a managing at least 50 % of these cases in South Australia.
Costs of treatment were calculated from patient-level resource data collected by the ACS over several years via medical chart review 6 and, for endoscopic therapies, from patient-level data collected from hospital records in South Australia (excluding dilatation for strictures). Costs also included ongoing monitoring and testing procedures by whether a patient had or had no surgery and derived from the ACS patient dataset. These individual costs are pooled and termed "follow-up costs" (Table 1 ). Prices applied to resource use were taken from national price schedules and public hospital clinical costings for inpatient surgical stays. The mean cost of an esophagectomy included in-hospital adverse events (e.g., anastomotic leak, infections, pneumonia) and intensive care unit admissions for some patients. 6 Statistical analyses of costs allowed for their skewed nature. 10 Australian life tables provided information on background all-cause mortality.
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Utility scores to adjust survival estimates in estimating quality-adjusted life-years were obtained from a literature review on utility weights for treatments for esophageal adenocarcinoma. [12] [13] [14] [15] Sensitivity analyses were undertaken to address the potential uncertainty of these estimates on the base case results. Table 1 lists all data estimates and tabled data in the model with their respective sources and ranges tested in sensitivity analyses (see below). In addition, based on ACS and Adelaide datasets, treatment probabilities for neoadjuvant therapy plus surgery across tumor stages ranged from 0.62 (T2) to 0.81 (T4), 0.71 to 0.77 for surgery without neoadjuvant therapy, 0.02 to 0.06 for perioperative deaths, 0.19 to 0.42 for being alive at 5 years following surgical treatment, and 0.26 to 0.48 for being alive at 5 years following neoadjuvant with surgical therapy.
Analyses
Using a natural history model with current practice, we estimated the economic outcomes for treatment options connected with actual patterns of care for managing patients with a diagnosis of HGD or esophageal adenocarcinoma. Our analysis took an Australian health system perspective when measuring and valuing health care resources. Costs were valued in 2009 Australian dollars and converted to 2009 US dollars using a purchasing power parity of 1 AUD01.553 USD. 16 All dollars presented here are USD ($). Further details on the resource quantities and medical costs have been published previously. 6 Costs and quality-adjusted life-years were discounted at 5 % annually. The costs and effects of current practice were compared with the hypothetical scenarios described in Table 2 and incremental net monetary benefit (net benefit) generated. For comparing the current treatment with each hypothetical scenario separately, incremental net benefit was calculated over a 5-year period as:
where λ0$50,000 was the base case threshold value applied to incremental quality-adjusted life-years gained (ΔE) and ΔC is the incremental cost. A decision-making threshold of $50,000 was used. The strategy with the highest positive incremental net benefit (hereafter called "net benefit") is the preferred option, whereas a negative net benefit indicates a net loss and such a strategy should not be adopted.
Sensitivity Analyses
Probabilistic sensitivity analyses on net benefit were undertaken to examine the joint variation possible within the data point estimates used in the model, based on their known (Table 1) . Where patient-level data were used (e.g., from the ACS), the distributions assigned were based on means, standard deviations, and medians, where appropriate. The analyses were conducted by resampling from the nominated parameter distributions across 5,000 iterations (Monte Carlo simulation). Simulated mean net benefits with 95 % uncertainty intervals (95 % UI) were generated to estimate the extent of uncertainty for each comparison.
Alternative Management Scenarios
To evaluate the impact of changing clinical practice and outcomes, five hypothetical scenarios were tested. These involved changing current therapy by:
1. Altering the proportion of patients with stage T1 adenocarcinoma undergoing EMR; 2. Modifying perioperative mortality rates for esophagectomy; 3. Increasing the proportion of patients diagnosed at earlier stages (to explore the potential outcomes only of early detection or surveillance);
4.
In patients undergoing neoadjuvant chemotherapy, adding fluorodeoxyglucose (FDG) PET after the first cycle of chemotherapy to assess tumor response, and modify treatment to progress directly to surgery if poor response; and 5. Increasing the proportion of patients undergoing definitive chemoradiotherapy as first-line therapy.
Full details and the rationale behind each of the five scenarios are given in Table 2 .
Results
Over 5 years, the total medical cost for treating an individual with esophageal adenocarcinoma varied between $33,572 and $50,226, depending on T stage (Table 3) . Costs were $8,267 for patients with distant metastases. Over 5 years, survival ranged from 0.97 to 4.66 years with a mean 2.5 years for T stages T2 and T3. Patients with HGD incurred fewer costs ($23,179) than patients with invasive adenocarcinoma, with the small number of deaths due to other causes. Overall, current treatment patterns for HGD and adenocarcinoma of the esophagus had mean qualityadjusted life-years of 2.25 and mean costs of $41,345 over 5 years (Table 3) . Compared with current treatment costs and outcomes for HGD and esophageal adenocarcinoma, the greatest additional net benefit per patient among the five scenarios of interest was observed for potentially downstaging T3 tumors through earlier detection (Table 4 ). The incremental net benefit was $4,971 (95 % UI, $1,560-8,368) for a 20 % reduction in the proportion of patients presenting with stage T3 disease, redistributed equally to T2, T1, and HGD (Table 4) , corresponding to modest gains from a hypothetical early detection process. However, this excludes the costs of an early detection or surveillance program which would be required to fully evaluate this strategy. Net benefits were relatively modest but positive (cost-effective) for a perioperative mortality rate of 1 % (net benefit, $233; 95 % UI, −$297 to $95), increasing the use of EMR treatment in patients with T1 stage adenocarcinoma (e.g., 100 % T1a+25 % T1b: net benefit, $428; 95 % UI, $182-726) and adding FDG-PET for assessing response to neoadjuvant therapy (net benefit, $805; 95 % UI, $59-1,596) and increasing the use of chemoradiotherapy in T2 and T3 by 25 % (net benefit, $2,660; 95 % UI, −$1,716 to $9,712) ( Table 4 ). Net benefits were positive but inconclusive for the use of chemoradiotherapy as definitive treatment for T2 and T3 cancers (replacing esophagectomy as definitive treatment), as indicated by the 95 % limits spanning across expected net loss to net benefit (Table 4) .
Discussion
Cost-effectiveness analysis is the process of systematically comparing the relative health care costs and benefits of alternative strategies to inform decision-makers of the strategy or treatment pathways with highest net benefit, 17 as well as those likely to provide better value if implemented more widely, and areas which might benefit from further research. [18] [19] [20] Systematic assessment of incremental costs and effects requires consideration of natural history and interaction with practice, and this is particularly important for conditions such as esophageal adenocarcinoma which has multiple strategies and pathways for monitoring, diagnosis, and management, all conditional on the stage of disease at presentation 21 . While costs might be of secondary concern to clinicians who primarily seek to optimize outcomes for individual patients, ultimately, resource allocation decisions do affect everyday clinical care in settings with budgetary pressures. 22 It is mandatory for regulatory bodies in Canada, UK, Australia, and most of the Western world to evaluate cost-effectiveness of new technologies when considering potential government reimbursement.
Our results suggest that, compared with current practice, potential incremental net benefit, at a threshold value of $50,000 per quality-adjusted life-year, is greatest for early detection in the context of a Barrett's esophagus surveillance program which shifts the proportion of patients presenting with stage T3 cancer to earlier stages (e.g., $4,971 with 20 % downshift in T3). This is due to this strategy having a marked impact on both increased survival prospects and lower costs associated with treatment pathways for patients with stage T1 adenocarcinoma or HGD. However, the cost to implement early detection strategies (e.g., surveillance, detection through biomarker screening) is not included in the net benefit results and will have the impact of reducing this net benefit. Further modeling will be required to evaluate this. Our model suggests that, if early detection strategies can downstage 20 % of individuals with T3 stage to HGD or T1, the cost cannot exceed $4,971 per patient for it to be a worthwhile health care investment.
Since there are currently only a small proportion of patients presenting with stage T1 adenocarcinoma (15.2 %) or HGD (2.2 %) relative to stage T2-T4 adenocarcinoma, the economic impact of strategies which only improve the outcome for early stages, but not increase the proportion presenting with early stage disease, is likely to be quite modest when evaluated in the context of the overall population. On the other hand, strategies that increase the proportion with early stage disease by shifting people from late stage to early stage might be more promising and do not depend on the development of new technologies or devices. This was shown in our findings when, for example, where hypothetically an increased proportion of patients with stage T1 adenocarcinoma underwent EMR rather than esophagectomy produced a net benefit of only $428, a much smaller gain than for early detection strategies. Despite this, our results support the use of EMR for T1 tumor treatment as shown by the positive net benefit. This result is also consistent with previous health economic reports of endoscopic techniques as preferred treatments for HGD and stage T1 adenocarcinoma versus esophagectomy. 23, 24 Utility scores following esophagectomy over the longerterm and the cost for esophagectomy were critical parameters in our natural history model. The high cost of the hospital episode for esophagectomy is also reflected in the analyses HGD high-grade dysplasia, QALYs quality-adjusted life-years and includes the costs of complications following such procedures. Surgical treatment is complex, and it is common for adverse events to occur, resulting in lengthy hospital stays and longer recovery periods in some patients. Previous work on patient-level resource data that formed the basis of the cost estimates modeled here showed that 24 % of the patients undergoing esophagectomy experienced at least one significant complication and the mean length of stay for the surgical episode was 15.5 days. 6 Many of the patients undergoing esophagectomy were hospitalized for a much longer period of time. 6 whereas RFA and EMR are typically same-day procedures. However, these endoscopic procedures usually require several procedures per patient to complete a course of treatment. 1 In assessing the subset of patients specifically with stage T1 adenocarcinoma or HGD, our results suggest that some economic efficiency might be gained from treatment pathways which involve less-invasive endoscopic therapies. This is driven by reduced treatment-related morbidity and mortality and lower costs compared to surgery.
In our study, hypothetically modeling different mortality rates for esophagectomy yielded different outcomes. When mortality rates were 5 or 10 %, there was no net benefit for the use of esophagectomy, although there was a benefit for mortality rates of 0, 1, and 3 %. This suggests that the perioperative rate for esophagectomy has a critical impact on whether or not this procedure is clinically effective and cost-effective in patients with early stage disease, and it is likely that perioperative mortality rates of no more than 3 % are required for esophagectomy to be an appropriate procedure for the treatment of these patients.
Mortality associated with esophagectomy has progressively declined over recent decades. A review of esophagectomy outcomes for the 1990s showed a hospital mortality rate of 8.8 % for this decade, 25 although lower More recent reports from the 2000s describe mortality rates of 3-5 %, again with lower mortality rates consistently reported from high-volume centers. 27 A study from our centers described an in-hospital mortality rate for esophagectomy in five Australian hospitals of 3.5 %. 28 A lower mortality rate of 1.2 % has been reported for esophagectomy in patients specifically presenting with stage T1 adenocarcinoma or HGD. 29 Our current study supports surgical treatment for early stage esophageal cancer only in centers which can consistently achieve mortality rates for esophagectomy of 3 % or less for patients with this disease stage.
Our study has a number of limitations. Despite the use of large Australian-based datasets, which reflect recent health care utilization and the natural history of esophageal adenocarcinoma, a number of gaps remained for uncommon pathway probabilities and it was necessary to depend on published reports or even clinical judgment for some of these. In part, this occurred because ablation therapies are relatively new. The esophageal surgeons contributing to the development of this model all worked in high-volume hospitals. Several surgeons have extensive personal experience with endoscopic ablative therapies. 30, 31 While using "expert opinion" may have introduced some bias, this was counteracted by testing across a distribution of plausible values to address the potential uncertainty. As a developed country with similar patient profiles and treatment practices to the US setting. 8 we expect that patterns of care in Australia would be broadly comparable to the USA and Northern Europe. However, different pricing schedules across countries may limit the generalizability of our cost estimates. The relative costs of the different procedures should be similar and the quantities of resources used are predicted to be stable. The choice of 5-year time horizon was used to match the patient and health outcomes for which we had data. This interval captures the vast majority of mortality events and health services for patients following treatment. However, this time period is unlikely to capture the majority of mortality events for patients with HGD (2.2 % of the base cohort) and thus limits the interpretation of results for this subset of patients for whom long-term data are unavailable. Finally, utility scores, similar to health-related quality of life assessments, from Australian patients were unavailable and, therefore, we relied on those reported in the literature for US and European populations.
The implications of our modeling lend support to measures that promote earlier presentation of tumors, such as developing risk factor assessment processes and endoscopic surveillance of Barrett's esophagus. This has been a particularly contentious topic with health economic studies producing mixed results as to the cost-effectiveness of endoscopic surveillance of Barrett's esophagus. 5 In 2009, two US studies recorded mean costs per patient under surveillance of $2,769 32 and $11,532 33 for surveillance programs involving five-yearly screening intervals, and $7,940 was reported for one UK study with three-yearly intervals (converted to $2,009). 13 Our cost cutoff of $4,971 per patient within an early detection program appears to be in the overall range of these costs. However, research is still needed to explicitly model the long-term economic impact of surveillance of Barrett's esophagus, and this should incorporate natural history models for current treatment, intervention resources, screening intervals, and adverse events.
There is widespread interest in improving health outcomes for patients with esophageal adenocarcinoma and, in particular, diagnosing this disease at an earlier stage, so that less invasive endoscopic options such as mucosal ablation and EMR can be applied. The majority of patients currently present with stage T2-T4 tumors, and only a minority present with early cancer or HGD. Consequently, to improve outcomes, the most promising cost-effective approach might be early detection to avoid esophagectomy, chemotherapy, and radiotherapy. Our data suggest that this requires downstaging of at least 20 % of T3 tumors to stage T1 or HGD, at a cost of less than $4,971 per patient under surveillance.
range of all responses collated. Consensus was reached via e-mail correspondence after the surgeons were given the opportunity to agree/disagree with the group range. An average was taken of each estimate for the baseline model and range included in the sensitivity analyses. The surgeons were chosen from high-volume centers and with an active interest in esophageal cancer research. The locations spanned two Australian states and surgeons worked in private and public hospital settings.
